* more than 24h has elapsed since ccu admission. * death is deemed to be imminent and inevitable during the next 24h. * one or more of: the patient, substitute decision-maker or the attending physician are not committed to full active treatment. * known condition resulting in ongoing immunosuppression including neutropenia (count \< 1.5 x 10\^9/l) prior to hospitalisation, malignancy, latent tuberculosis or chronic liver disease (if known). * previous or current treatment with anakinra or medication suspected of interacting with anakinra, listed in the drug smpc, known at the time of trial entry or previous participation in this trial. * known to have received active treatment in a clinical trial of an investigational immunomodulatory agent (not including corticosteroids) within 30 days prior to study entry. * known to be pregnant or breast feeding or inability to reliably confirm that the patient is not pregnant. * known allergy to anakinra or any of the excipients listed in the drug smpc * known allergy to other products that are produced by dna technology using the micro-organism e. coli (e.g. escherichia coli derived protein).

* more than 24h has elapsed since ccu admission. * death is deemed to be imminent and inevitable during the next 24h. * one or more of: the patient, substitute decision-maker or the attending physician are not committed to full active treatment. * known condition resulting in ongoing immunosuppression including neutropenia (count \< 1.5 x 10\^9/l) prior to hospitalisation, malignancy, latent tuberculosis or chronic liver disease (if known). * previous or current treatment with anakinra or medication suspected of interacting with anakinra, listed in the drug smpc, known at the time of trial entry or previous participation in this trial. * known to have received active treatment in a clinical trial of an investigational immunomodulatory agent (not including corticosteroids) within 30 days prior to study entry. * known to be pregnant or breast feeding or inability to reliably confirm that the patient is not pregnant. * known allergy to anakinra or any of the excipients listed in the drug smpc * known allergy to other products that are produced by dna technology using the micro-organism e. coli (e.g. escherichia coli derived protein).

- more than 24h has elapsed since ccu admission. - death is deemed to be imminent and inevitable during the next 24h. - one or more of: the patient, substitute decision-maker or the attending physician are not committed to full active treatment. - known condition resulting in ongoing immunosuppression including neutropenia (count < 1.5 x 10^9/l) prior to hospitalisation, malignancy, latent tuberculosis or chronic liver disease (if known). - previous or current treatment with anakinra or medication suspected of interacting with anakinra, listed in the drug smpc, known at the time of trial entry or previous participation in this trial. - known to have received active treatment in a clinical trial of an investigational immunomodulatory agent (not including corticosteroids) within 30 days prior to study entry. - known to be pregnant or breast feeding or inability to reliably confirm that the patient is not pregnant. - known allergy to anakinra or any of the excipients listed in the drug smpc - known allergy to other products that are produced by dna technology using the micro-organism e. coli (e.g. escherichia coli derived protein).

- more than 24h has elapsed since ccu admission. - death is deemed to be imminent and inevitable during the next 24h. - one or more of: the patient, substitute decision-maker or the attending physician are not committed to full active treatment. - known condition resulting in ongoing immunosuppression including neutropenia (count < 1.5 x 10^9/l) prior to hospitalisation, malignancy, latent tuberculosis or chronic liver disease (if known). - previous or current treatment with anakinra or medication suspected of interacting with anakinra, listed in the drug smpc, known at the time of trial entry or previous participation in this trial. - known to have received active treatment in a clinical trial of an investigational immunomodulatory agent (not including corticosteroids) within 30 days prior to study entry. - known to be pregnant or breast feeding or inability to reliably confirm that the patient is not pregnant. - known allergy to anakinra or any of the excipients listed in the drug smpc - known allergy to other products that are produced by dna technology using the micro-organism e. coli (e.g. escherichia coli derived protein).